The Clinical Diagnostics Service of the Molecular Otolaryngology and Renal Research Laboratories is a Joint Commission-approved CLIA-accredited diagnostic laboratory.
Dense Deposit Disease; C3 Glomerulonephritis and atypical Hemolytic Uremic Syndrome
CH50 measures total hemolytic activity of the classical and terminal pathways using sensitized sheep erythrocytes. CH50 can be low if complement components in the classical pathway (C1, C4, C2, C3) or terminal pathway (C5 through C9) are reduced or absent. Since most patients with C3G (especially DDD) have exceedingly low plasma C3 levels, their CH50s are also typically low.
Indications for screening
CH50 is a screening test for many diseases associated with complement activation.
MORL screening methodology
Turnaround time is ~2 weeks.
1 ml frozen serum (see testing requisition for specimen handling).
Cost & CPT Codes
See the MORL testing menu